Exploratory Subgroup Analysis for TAILORx and NSABP B-20 indicate that Recurrence Score® and age are the strongest predictors of chemotherapy benefit1. The absolute reduction of distant recurrence from chemotherapy for patients >50 years and ≤50 years is shown here for RS groups: 11-15, 16-20, and 21-25 from TAILORx, and 0-10 and 26-100 from NSABP B-202.
Estimated Chemotherapy Benefit for Individual Recurrence Score Results
Recurrence Score ranges shown reflect randomized patients in NSABP B-20 and TAILORx.
Node Positive References
- Albain et al.Lancet Oncol. 2010.
- ER Score based on quantitative ESR1 expression (estrogen receptor); PR Score based on quantitative PGR expression (progesterone receptor).
- Badve SS, Baehner FL, Gray RP, et al. “Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.” J Clin Oncology, 2008 May 20;25(15):2473-81
- ASCO Annual Meeting 2005 Abstract #510 by S. Paik et al.
Disclaimer: These case studies are brought to you for educational purposes only and should not be interpreted as an endorsement of Exact Sciences or its services by the submitting physician. The information reflects the interpretive diagnostic opinions of the treating physicians and is not intended to represent a standard of care. The case studies describe real-life cases of patients who have been prescribed the Oncotype DX® test. They are not necessarily representative of all tested patients, and the result in any given case will vary. The examples are not necessarily representative of all of those who will use our clinical tests. Exact Sciences does not endorse any of the contributors featured on this site and takes no view as to the treatment decisions reported in these cases.